The Latest Breaking News from MedTech

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

Amid ongoing uncertainties surrounding the economy and global power dynamics, market volatility continues to dominate. In such times, investing in fundamentally sound blue-chip stocks, Johnson & Johnson (JNJ), American Express (AXP), and AT&T (T), could offer investors a stable foundation, serving as a buffer against market fluctuations and uncertainty. Read…

Despite Becton, Dickinson and Company’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Medtech giant Stryker has outperformed the broader market over the past year, and analysts remain moderately bullish on the stock’s prospects.

MedTech is a promising market driven by rising disease prevalence, innovative healthcare solutions, and significant growth in digital health technologies. Thus, adding strong MedTech stocks like Becton, Dickinson (BDX), Abbott (ABT), and Medtronic (MDT) to your watchlist could be wise as innovation in healthcare accelerates. Read more….

The FDA recently approved two key features of popular Apple devices.

MedTech stocks are at the forefront of revolutionizing healthcare with the dynamic growth potential of technology. Amid this backdrop, it could be wise to consider investing in companies like Medtronic (MDT), STERIS (STE), and Hologic (HOLX), which are transforming the way healthcare is delivered and tailoring it to individual patient…